Rao Prabhala

Dr. Prabhala received his MS in Soil Microbiology from A. Nagarguna University in Guntur, India in 1977. He completed his second MS in Medical Microbiology from California State University-LA in 1985. He received his PhD in tumor immunology from the University of Arizona-Tucson in 1989. He went on to complete his post-doctoral fellowship in mucosal immunology at Dartmouth Medical School in 1991. After working in medical schools and the pharmaceutical industry, he joined the Dana-Farber Cancer Institute as an instructor in 2000.

Publications

Prabhala RH, Neri P, Bae JE, Tassone P, Shammas, MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006, 107:301-4.

Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB, Li C, Catley L, Prabhala R, Anderson KC, Munshi NC. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun 15;178(12):7730-7.

Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013; 190(3):1360-71.

Biernacki MA, Tai YT, Zhang GL, Alonso A, Zhang W, Prabhala R, Zhang L, Munshi N, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Brusic V, Anderson KC, Wu CJ. Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation, Blood. 2012, 119(13):3142-50.

Fulciniti M, Amin S, Nanjappa P, Rodig SJ, Prabhala R, Li C, Minvielle S, Tai YT, Tassone P, Avet-Loiseau H, Hideshima T, Anderson KC, Munshi NC. Significant biological role of Sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011, 17(20):6500-9.

Bae J, Carrasco R, Lee A-H, Prabhala RH, Tai Y-T, Anderson KC, Munsh NC. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia, 2011, 25(10):1610-9.

Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010, 115(26):5385-92.

Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD Jr, Annunziata CM, Munshi NC. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010, 115:2827-34.

Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith ES, Wang W, Prabhala R, Tai YT, Tassone P, Anderson KC, Munshi NC. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 15:7144-52. 2009.

Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP, Exley MA, Munshi NC. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 14(21):6955-62. 2008.

Blotta S, Tassone P, Prabhala RH, Tagliaferri P, Cervi D, Amin S, Jakubikova J, Tai YT, Podar K, Mitsiades CS, Zullo A, Franco B, Anderson KC, Munshi NC. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood.114:3276-84, 2009.

Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA4, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, and Munshi NC. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for Multiple Myeloma. Blood. 114:371-9, 2009.

Jinushi M, Matthew Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. PNAS, 105:1285-90, 2008.

Prabhala, RH, Munshi, NC. Immune Therapies. Hematol Oncol Clin North Am. 21:1217-30, 2007.